reactive oxygen species; statin; thyroxin CARDIAC HYPERTROPHY resulting in heart failure is a major cause of death worldwide (23) . Both cardiac hypertrophy and its progression to failure have been suggested to be regulated by common signaling pathways (26) . Recent studies (17, 26, 28) have demonstrated that NADPH oxidase is important in the pathogenesis of several aspects of cardiac remodeling and its antecedent conditions, largely through actions on redox-sensitive signal transduction. NADPH oxidase is a multicomponent enzyme complex that consists of membrane-bound cytochrome b-558, which is a heterodimer of gp91 phox and p22 phox , cytosolic regulatory subunits p47 phox and p67 phox , and the small GTP-binding protein Rac1 (26) . Rac1 plays many important biological functions in cells, but perhaps the most unique function of Rac1 is its ability to bind and activate the NADPH oxidase complex (13) . It has been reported that in human heart failure, increased NADPH oxidase-dependent ROS production is coupled with increased membrane expression and activity of Rac1 (26) . In addition, increased Rac expression has been reported to be associated with cardiac dilation (36) . Furthermore, a previous study (24) in isolated cardiomyocytes from transgenic mice overexpressing Rac1 in the myocardium showed the importance of cardiomyocyte Rac1 in the development of cardiac hypertrophy. Moreover, we (14) have previously reported that constitutive overexpression of human Rac1 in smooth muscle cells results in increased vascular superoxide (O 2 ·Ϫ ), hypertension, and mild cardiac hypertrophy in transgenic mice.
Rac1 activation induces a downstream signaling cascade, such as MAPK or JNK family members (2, 36, 45) , p21-activated kinase (40) and focal adhesion kinase (9) . Stimulation of these kinases apparently changes phosphorylation of cardiomyocyte proteins, with MAPK or JNK signaling leading to hypertrophy (39) . In addition to Rac1/ROS signaling, many other signaling pathways can feed into the activation of these kinases, e.g., integrins. Integrins are a class of membrane receptors that, collectively with a number of linked cytoskeletal proteins, join the sarcomeric contractile apparatus to the extracellular matrix across the plasma membrane and elicit intracellular signaling pathways, promoting the cardiomyocyte hypertrophy program (25, 30) .
It is becoming progressively clear that plants and animals share a number of common signal transduction elements. One of the most apparent analogies so far has been the finding that plants have genes that demonstrate high homology to animal and yeast genes coding for small signal-transducing, GTPbinding proteins of the ras superfamily (8) . In addition, it has been reported that Rac proteins in plants could be involved in multiple processes, such as the oxidative burst through activating NADPH oxidase (41) , organization of the actin cytoskeleton (44) , and cellular morphology (42) , indicating that plant Rac proteins may have similar functions as Rac/Cdc42 in yeast and animal cells (41) . Furthermore, we (15) have previously shown that ZmRacD expression in an in vitro mammalian system, NIH 3T3 cells, produced higher levels of O 2 ·Ϫ than human Rac1 and other Rac isoforms from Zea maize (15) . This confirms the remarkable functional and structural conservation of Rac protein between plant and animal kingdoms during evolution and that ZmRacD is a stronger activator of the oxidative burst than the mammalian one in vitro (15) . Therefore, the goal of the present study was to assess the effect of ZmRacD-mediated high levels of O 2 ·Ϫ on the hearts of transgenic mice. However, the ZmRacD gene has 69% similarity and 62% identity at the amino acid level to mammalian Rac1 (15) . Consequently, we hypothesized that this low overall homology may decrease the cellular interactors toward ZmRacD, resulting in a milder phenotype. This could enable our model to gradually develop a cardiac phenotype with aging and provide an executable window to investigate the pathological conditions involved in the progression of Rac-induced diseases.
The ZmRacD model was developed in our laboratory by transgenic overexpression of a constitutively active mutant of ZmRacD cDNA specifically in the hearts of FVB/N mice using a mouse ␣-myosin heavy chain (␣-MHC) promoter. 85-23, Revised 1996) . For this study, we used male ZmRacD transgenic mice and age-matched nontransgenic controls. Unless otherwise stated, all the experiments were repeated three times and were performed with heterozygous ZmRacD transgenic mice (8 -24 mo old) with age-matched nontransgenic littermates. Six to eight mice per genotype were used for each experiment.
METHODS

Animals
Generation and identification of ZmRacD transgenic mice. The ␣-MHC-RacD transgene was constructed using cDNA of a constitutively active mutant of the ZmRacD gene (16) linked to the 5.5-kbp mouse ␣-MHC promoter (per Ref. 35 ; gift of J. Robbins, University of Cincinnati, Cincinnati, OH). The C22 plasmid containing the 5.5-kbp mouse ␣-MHC promoter was cut with Sal1 and Kpn1 restriction enzymes to link ZmRacD to the promoter. The cDNA of ZmRacD, including its polyadenylation tail, was cut with the same restriction enzymes (Sal1/Knp1) and cloned within the Sal1 and Kpn1 ends of the C22 plasmid that contained the 5.5-kbp mouse ␣-MHC promoter. The ␣-MHC promoter was used to induce selective overexpression of ZmRacD in myocytes. The Not1/Kpn1 fragment of this plasmid containing the transgene (ZmRacD cDNA under the control of the ␣-MHC promoter) was isolated and microinjected into mouse fertilized eggs of FVB/N females, as previously described (12) . Single cell embryos derived from superovulated FVB/N females were used for the microinjection procedure. Surviving microinjected embryos were implanted into pseudopregnant FVB/N foster mothers. Transgenic mice were identified as previously described (14) using PCR and specific primers for ZmRacD corn cDNA. The forward primer was 5=-AGGCGGTGGTCAACTTGTGT-3=, and the reverse primer was 5=-CTTCTTGTCCTGCTGTATCCC-3=. We screened all the transgenic founders we obtained, and the ones that had the highest expression of ZmRacD were selected (data not shown). In addition, the ZmRacD transgene was isolated from DNA obtained from tail clips of each founder. The transgene was characterized with specific restriction enzymes and then sequenced to ensure the integrity of the transgene and the lack of methylation, deletion, or mutations. These founders were used to establish the colony, and their offspring showed consistent cardiac effects (data not shown). Each mouse was genotyped when it was weaned, and only respective nontransgenic littermates served as wild-type (WT) controls. Experiments were performed on adult (8 mo) and old (20 -24 mo) male age-matched mice.
RT-PCR. To detect and verify the expression levels of ZmRacD in different organs, frozen tissues from transgenic mice were analyzed by RT-PCR as described in our previous reports (14, 15) using ZmRacD-specific primers, as described above. Briefly, frozen tissues were pulverized in liquid nitrogen by mortar and pestle. Total cellular RNA was extracted from various frozen mouse tissues using TRIzol reagent (Invitrogen), and the integrity of total RNA was checked on an agarose gel. Total RNA samples from different tissues were treated for 15 min with DNase 1 (1 unit/1 g total RNA) to eliminate any possible genomic DNA contamination. The reaction was inactivated by the addition of 1 l of 25 mM EDTA to the reaction mixture, and the mixture was then heated for 10 min at 65°C. First-strand cDNA was synthesized using Superscript II (GIBCO-BRL). It was then amplified using Taq DNA polymerase with 35 cycles of denaturation (94°C, 1 min), primer annealing (53.5°C, 1 min), and extension (72°C, 2 min). The ZmRacD-specific primers were used for the PCR. On each sample, a negative control (DNase 1, no primers or irrelevant primers) and positive control (no DNase 1) were performed.
Echocardiography. In vivo cardiac dimension and contractile function in both WT and transgenic mice were evaluated using a highfrequency ultrasound imaging system (VEVO 2100, Visual Sonics, Toronto, ON, Canada) at the Heart and Lung Research Institute. Experimental mice were anesthetized with isoflurane at a concentration of 2% and then maintained at 1% isoflurane using nasal prongs during the whole procedure. Measurements were taken from the parasternal short-axis view in M-mode to view left ventricular (LV) movements during diastole and systole corresponding to the electrocardiogram. All data and imaging were analyzed by the Visual Sonics Cardiac Measurements Package.
MRI for mouse hearts. Cardiac images for both WT and transgenic mice were assessed using MRI instrument Bruker 500 at the Heart and Lung Research Institute. Mice were anesthetized with 2.5% isoflurane mixed with 1 l/min carbogen and maintained with 1-1.5% isoflurane. Physiological parameters, such as electrocardiogram and respiration, were monitored using a monitoring system (model 1025, Small Animals Instruments, Stony Brook, NY). Short-axis images of the mouse heart were acquired so as to cover the whole LV (FLASH sequence; parameters: repetition time/echo time, 130/1.4 ms; matrix, 256 ϫ 192; field of view, 3 ϫ 3 cm; slice thickness, 1 mm; 16 frames/cardiac cycle). These images were used to compute hemodynamic parameters such as ejection fraction (EF) and stroke volume. ImageJ software was used for image analysis. The total period of imaging was ϳ40 min (10 min for initial adjustments followed by 30 min of data acquisition).
Histology. Age-matched WT and transgenic hearts were processed in 10% neutral buffered formalin. Standard hematoxylin and eosin (H&E) staining and Masson's trichrome staining were performed on 6-m sections from formalin-fixed and paraffin-embedded midventricles. Digital images of each slide were taken for morphometric evaluation using MetaMorph software (version 4.6), and collagen deposition areas in both ventricles were calculated in duplicates from different animals. In addition, another set of paraffin sections (4 m) were stained with Masson's trichrome. Three to five images per heart were acquired with a ϫ40 objective with a Nikon Eclipse TS-100F inverted microscope equipped with a Lumenera Infinity 1-2C camera (Nikon Instruments, Melville, NY) for measuring the length and cross-sectional area of cardiomyocytes using MetaMorph image analysis software 7.1.2.0 (Molecular Devices). For a more detailed description of the quantification method, see the Supplemental Material. Immunocytochemistry. Immunofluorescence staining of myocardial Rac was performed as previously described (7) . Frozen sections (6 m) from the hearts were fixed with 2% paraformaldehyde for 5 min. The cell membrane was permeabilized with 0.5% Triton X-100 (1ϫ PBS) for 15 min followed by 30 min of incubation with normal goat 1 Supplemental Material for this article is available at the American Journal of Physiology-Heart and Circulatory Physiology website. serum (Jackson ImmunoResearch) to block nonspecific binding. After being washed with PBS (1ϫ), sections were incubated overnight with the following primary antibodies: monoclonal anti-mouse cardiac MHC antibody (cardiomyocyte-specific antibody, 1:50, Abcam) and polyclonal anti-rabbit Rac1 (1:250, Millipore). The secondary antibodies used to visualize the attachment of the primary antibodies were goat anti-mouse conjugated with Alexa fluor 488 and goat anti-rabbit conjugated with Alexa fluor 594 (Invitrogen). Nuclei of the cells were stained with hard set mounting medium containing 4,6-diamidino-2-phenylindole (Vector Laboratories).
Measurement of O 2 ·Ϫ levels in mouse hearts. In situ production of myocardial O2
·Ϫ was assessed by the oxidative fluorescent dye dihydroethidium (DHE) as previously described (21) . Cell-permeable DHE is oxidized to fluorescent hydroxyethidine by O2 ·Ϫ and then intercalated into DNA. Briefly, hearts from both WT and transgenic mice were placed immediately in ice-cold PBS, washed, and then embedded in OCT for cryosectioning. Frozen sections (6 m) from the hearts were incubated with DHE (10 M, Sigma-Aldrich) for 30 min at 37°C in a dark chamber. After being washed with PBS, sections were fixed with aqueous mounting medium (Gel Mount, Sigma), and images were obtained using a fluorescence microscope (Nikon TE 300). Red fluorescence intensity was determined using MetaMorph image analysis software 7.1.2.0 (Molecular Devices).
Western blot analysis. Western blots were performed to determine the relative cardiac expression of Rac1, ␣ 1-and ␤1-integrins, integrinlinked kinase (ILK), ERK1/2, phosphorylated (p-)ERK1/2, JNK, and p-JNK in both WT and transgenic mice, as described in our previous reports (16, 27) . To detect ZmRacD protein levels, we used a mouse monoclonal antibody raised against human Rac1 (1:1,000, Millipore) that cross-reacts with ZmRacD. Membranes were also incubated with specific antibodies for ␤1-integrin, ILK, p-ERK1/2, p-JNK (1:1,000, Cell Signaling), ␣ 1-integrin (1:200, Santa Cruz Biotechnology), or JNK and ERK1/2 (1:500, Santa Cruz Biotechnology). Secondary antibodies were goat anti-rabbit and anti-mouse horseradish peroxideconjugated IgG (1:2,000, Santa Cruz Biotechnology). Antibody signals were detected by an enhanced chemiluminescence kit (Pierce), and GAPDH (1:3,000, Cell Signaling) was used as an internal control for equal protein loading.
Rac1 glutathione-S-transferase-p21-activated kinase pulldown assay. Heart tissues of both WT and transgenic mice were lysated and analyzed for the activation of Rac1 as described in the manufacturer's protocol (Rac/cdc42 Assay Reagent, no. 14-325, Millipore) and our previous report (14) .
Pravastatin treatment. Commercially available pravastatin tablets were purchased from HealthWarehouse. Tablets were ground with mortar and pestle and then dissolved in water and filtered. The pravastatin concentration in the water filtrate was confirmed by HPLC analysis as previously described by Önal and Sagirli (29) against standard pravastatin (Sigma). Eight-month-old WT and transgenic mice (n ϭ 24) were divided into three groups and were treated over a 4-wk period. Each of the three groups received the following treatment: intraperitoneal vehicle (WT, n ϭ 8), intraperitoneal vehicle (transgenic, n ϭ 8), and intraperitoneal pravastatin (10 mg/kg, transgenic, n ϭ 8). The dose of pravastatin, treatment period, and route of administration used in this study were based on previous reports (20, 22, 41) . At the end of the treatment period, animals were conducted for echocardiography. Directly after echocardiography, animals were killed, and hearts were excised and processed for further experiments.
Administration of thyroxin. Sodium-L-thyroxin (T4) was purchased from Sigma. T4 was prepared and injected as previously described (10) . Eight-month-old WT and transgenic mice (n ϭ 40) were divided into four groups and treated over a 2-wk period. Each of the four groups received the following treatment: intraperitoneal vehicle (WT, n ϭ 8), intraperitoneal T4 (200 g/kg, WT, n ϭ 8), intraperitoneal vehicle (transgenic, n ϭ 10), and intraperitoneal T4 (200 g/kg, transgenic, n ϭ 14). The treatment period and dose of T4 were decided by preliminary studies. Twenty-four hours after the last injection, animals underwent echocardiography. Directly after echocardiography, animals were killed, and hearts were excised and processed for further experiments.
Data analysis. Data are presented as means Ϯ SE. Data were analyzed by ANOVA followed by a Bonferroni post hoc test. P values of Ͻ0.05 were considered to be significant.
RESULTS
Generation and identification of transgenic mice. We engineered transgenic mice by overexpressing cDNA of the ZmRacD gene in FVB/N mice under the control of the mouse ␣-MHC promoter (Fig. 1A) . Comparison of deduced amino acid sequences of ZmRacD and human Rac1/Rac2 proteins showed 69% overall homology and 62% identity at the amino acid level. In addition, there was a high homology in the protein domain that interacts with NADPH (amino acid residues 26 -45 in humans and 29 -48 in ZmRacD mice); the conserved amino acids G (at position 12) and T (at position 17) were switched to amino acids V and N to generate dominant positive and negative mutants, respectively (Fig. 1B) . Transgenic mice were identified using PCR analysis of tail genomic DNA ( Fig. 2A) and were used to establish stable transgenic lines by breeding them with nontransgenic FVB/N littermates. RT-PCR analysis recognized selective ZmRacD transgene expression in the hearts of transgenic mice, and there was no expression in the liver, kidney, intestine, blood vessel, brain, and lungs (Fig. 2B) . Selective ZmRacD transgene expression in the cardiomyocytes of transgenic mice was further confirmed by immunostaining (Fig. 2C) .
Increased Rac expression and activity in the hearts of transgenic mice. To confirm the overexpression of ZmRacD protein in the hearts of transgenic mice, we performed Western blot analysis using an antibody raised against human Rac1 that cross-reacts with ZmRacD. Our results showed significant increases in ZmRacD protein expression in the hearts of both adult and old transgenic mice compared with endogenous Rac1 protein in adult WT hearts (166% and 262%, respectively, P Ͻ 0.001; Fig. 3A) . Moreover, the Rac1 glutathione-S-transferase (GST)-p21-activated kinase pulldown assay showed a significant increase in the activity of Rac protein in the hearts of adult transgenic mice (223%) compared with adult (P Ͻ 0.001) and old (P Ͻ 0.01) WT mice. In addition, old transgenic mice showed a highly significant difference (372%, P Ͻ 0.001) compared with all groups (Fig. 3A) . Similarly, there were significant increases in Rac1 expression and activity in the hearts of old WT mice (170%, P Ͻ 0.001, and 162%, P Ͻ 0.01, respectively) compared with adult WT controls (Fig. 3A) .
Increased O 2
·Ϫ production in the hearts of transgenic mice. We (15) have previously shown that ZmRacD regulates the assembly and activation of the NADPH oxidase enzyme complex, producing high levels of O 2 ·Ϫ when expressed in mam- ·Ϫ generation with dihydroethidium in frozen sections of mice hearts. C: bar graphs for mean fluorescence intensity in arbitrary units (a.u.). In both A and C, the value from adult WT mice was assigned as 100% (n ϭ 8 mice/group). *Significant change compared with adult WT mice; **significant change compared with adult and old WT mice; #significant change compared with adult transgenic mice. malian tissues in vitro. In this study, DHE staining shows a significant increase of O 2 ·Ϫ levels in adult transgenic hearts (257%) compared with adult (P Ͻ 0.001) and old (P Ͻ 0.01) WT mice. Moreover, old transgenic mice showed a highly significant difference (462%, P Ͻ 0.001) compared with all groups (Fig. 3, B and C) . Similarly, old WT hearts exhibited significant increases in the levels of O 2 ·Ϫ (194%, P Ͻ 0.001) compared with adult WT controls (Fig. 3, B and C) . Concomitantly, expression of myocardial NADPH oxidase subunit gp91 phox was significantly increased in old transgenic hearts (258%, P Ͻ 0.001) compared with old WT mice (data not shown).
Development of cardiac hypertrophy and changes in the cardiac structure and function of transgenic mice. To assess the effect of increased ZmRacD activity in the hearts of transgenic mice, we performed both echocardiography and MRI analyses. Echocardiography and body weight data are shown in Table 1 . Initially, body weight did not significantly change in any of the WT and transgenic mice. However, there were significant increases in LV mass (P Ͻ 0.001) and the LV mass-to-body weight ratio (P Ͻ 0.001) in old transgenic mice compared with other groups. Although there was a slight significant increase in LV mass of old WT mice (P Ͻ 0.05) compared with adult WT mice, this increase was abolished after normalization to body weight. In addition, old transgenic mice showed a significant increase in systolic LV internal diameter compared with adult WT (P Ͻ 0.05), adult transgenic (P Ͻ 0.05), and old WT (P Ͻ 0.01) mice and in diastolic LV internal diameter (P Ͻ 0.05) compared with adult WT mice only. On the other hand, there was a significant decrease in cardiac systolic functions in old transgenic mice, as evidenced by decreased LV EF comapred and with that in adult WT (P Ͻ 0.01), adult transgenic (P Ͻ 0.01), and old WT (P Ͻ 0.001) mice and decreased fractional shortening (FS) (P Ͻ 0.001) compared with that in the other groups. However, there were no significant changes in other echocardiographic parameters. Consistently, MRI showed a markedly enlarged LV with a significantly increased LV mass-to-body weight ratio in old transgenic mice (P Ͻ 0.001) compared with the other groups (Fig. 4, A and E, respectively) . In addition, there was a clear increase in the systolic LV internal diameter and a significant decrease in EF of old transgenic mice (P Ͻ 0.001) compared with the other groups (Fig. 4, B and D, respectively) . However, MRI showed no significant change in the diastolic LV internal diameter among all groups (Fig. 4C) . Fig. 4 . MRI of mouse hearts. A: representative long-axis images of mouse hearts showing that the hearts of old transgenic mice were larger and more round shaped (white arrow). B and C: representative short-axis images of mouse hearts at end-systolic (B) and end-diastolic (C) states. D and E: percent ejection fraction (% EF; D) and left ventricular (LV) mass-to-body weight ratio (LV mass/BW; in mg/g; E) as estimated by MRI analysis (n ϭ 6 mice/group). **Significant change compared with adult and old WT mice; #significant change compared with adult transgenic mice.
Histological analyses of the mouse hearts.
To determine if increased ZmRacD activity in transgenic mice resulted in alterations in the gross heart weight and myocardial structure, we first assessed the heart weight-to-body weight ratio. Our results indicated a significant increase in the heart weight-tobody weight ratio in old transgenic mice (P Ͻ 0.01) compared with all other groups (Fig. 5, A and E) . Furthermore, light microscopic examination was performed on ventricular tissues stained by H&E and Masson's trichrome. H&E staining confirmed the cardiac hypertrophy in old transgenic mice, as indicated by the enlarged myocyte size, some myofiber disarray, and abnormal vacuolization compared with the other groups (Fig. 5B) . To measure the size of cardiomyocytes in the transgenic mice, we analyzed Masson's trichrome-stained sections from the ventricular area of hearts. We searched for both transversal and longitudinal sections through cardiomyocytes. For the transversal sections, we measured the cross-sectional area. There were no statistical differences between adult WT mice (226.36 m 2 ) and adult transgenic mice (236.48 m 2 ). A slight but statistically significant increase was observed in old WT mice (281.09 m 2 , P Ͻ 0.05) and an almost doubling of the sectional area in old transgenic mice (520 m 2 , P Ͻ 0.001), a difference that was highly statistically significant for all comparisons (Fig. 5, C and F) , despite the relatively high variability we observed in all samples. Cardiomyocyte length was measured in those instances where we could find them clearly delineated by intercalated discs at both ends. We found no significant differences between adult (38.86 m) and old WT (31.24 m) mice and between these and adult transgenic mice (31.24 m); however, old transgenic mice had longer cardiomyocytes (56.76 m, P Ͻ 0.05) in all comparisons (Fig.  5G ). In addition, interstitial fibrosis characterizing cardiac hypertrophy was confirmed by Masson's trichrome staining. In striking contrast to all groups, Masson's trichrome staining clearly demonstrated significantly higher levels of interstitial fibrosis in the ventricles of old transgenic mice (Fig. 5D ) with an extremely significant higher total collagen content (420%, P Ͻ 0.001; Fig. 5H ).
Increased expression of ␣ 1 -and ␤ 1 -integrins in the hearts of transgenic mice. Similar to Rac1/ROS signaling, integrins can elicit intracellular signaling pathways promoting the cardiomyocyte hypertrophy program (25, 30) . This study showed a significant increase in the expression of ␣ 1 -integrin (148.74%, P Ͻ 0.01; 145.07%, P Ͻ 0.01; and 223.67%, P Ͻ 0.001; Fig. 6A ) and ␤ 1 -integrin (142.8%, 138.6%, and 239.6%, P Ͻ 0.001; Fig. 6B ) in old WT, adult, and old transgenic mice, respectively, compared with adult WT control mice. In contrast, there were no significant changes in myocardial ILK expression among groups (Fig. 6C) .
Activation of hypertrophic signaling pathways in the hearts of transgenic mice. Increased ROS and ␣ 1 ␤ 1 -integrins in the hearts of transgenic mice can lead to the activation of ERK1/2 and JNK, key kinases in the hypertrophic signaling pathway (3, 46) . Expectedly, our results exhibited significant increases in phosphorylated ERK1/2 (295%, P Ͻ 0.001) and JNK (223%, P Ͻ 0.001) in the hearts of old transgenic mice compared with all other groups (Fig. 7, A and B) . Also, there was a significant increase in p-ERK1/2 in the hearts of old WT mice (187%) compared with adult WT (P Ͻ 0.001) and adult transgenic (P Ͻ 0.01) mice. In addition, there was a significant increase in p-JNK (151%, P Ͻ 0.001) compared with adult WT and adult transgenic mice (Fig. 7, A and B) . However, there were no significant changes in total ERK1/2 and total JNK protein levels among groups (Fig. 7, A and B) .
Decreased Rac activity by statin reduced integrin expression in the hearts of adult transgenic mice. To test the role of increased Rac activity in inducing integrin expression and causing the cardiac hypertrophy in our model, we inhibited Rac activity by statin, a well-known Rac inhibitor (1, 26) . Pravastatin did not alter the basal heart weight-to-body weight ratio or any of the basal echocardiographic parameters in adult transgenic mice (data not shown). However, our results showed a significant decrease in Rac activity in the hearts of treated transgenic mice (114%, P Ͻ 0.001) compared with untreated animals (165%), whereas there was no significant change in total Rac expression between treated and untreated transgenic mice (Fig. 8A) . Furthermore, inhibition of Rac activity by pravastatin resulted in significant decreases in the myocardial expression of ␣ 1 -and ␤ 1 -integrins in treated transgenic mice (122% and 112%, P Ͻ 0.001) compared with untreated animals (200% and 162%; Fig. 8, B and C) .
T 4 induced cardiac dilation and systolic dysfunction in the hearts of adult transgenic mice. The ZmRacD transgene was induced using T 4 to upregulate the ␣-MHC promoter (36, 37) . Our results showed increased Rac expression in the hearts of adult transgenic mice (148%, P Ͻ 0.01) compared with adult WT mice (100%). Furthermore, T 4 supplementation resulted in increased Rac expression in the hearts of adult WT mice (150%, P Ͻ 0.01) compared with untreated adult WT mice and resulted in a further increase in myocardial Rac expression in adult transgenic mice (208%, P Ͻ 0.001) compared with all other groups (Fig. 9, A and B) . In addition, echocardiography showed that increased Rac expression in the hearts of adult transgenic mice resulted in cardiac dilation, as indicated by increased systolic and diastolic LV internal diameters compared with all other groups (P Ͻ 0.001; Fig. 9, C-F) . Also, there was systolic dysfunction in the hearts of T 4 -treated adult transgenic mice, as demonstrated by decreased EF and FS compared with all other groups (P Ͻ 0.001; Fig. 9, G and H) .
DISCUSSION
The small GTP-binding protein Rac1 of the Rho subfamily has been implicated in various cardiovascular disorders, in- cluding vascular dysfunction, hypertension, cardiac hypertrophy, cardiac dilation, and heart failure (14, 26, 36) . Our previous report (14) showed that the constitutive overexpression of Rac1 in smooth muscle cells results in increased vascular O 2 ·Ϫ , hypertension, and mild cardiac hypertrophy in transgenic mice.
In the present study, we report on a new mouse model with myocyte-specific overexpression of the ZmRacD gene in the heart under the control of the mouse ␣-MHC promoter. The ZmRacD gene has 69% similarity and 62% identity at the amino acid level to mammalian Rac1. In addition, there is a high homology in the ZmRacD protein domain that interacts and binds to NADPH oxidase. We (15) have previously shown that ZmRacD produces a higher level of O 2 ·Ϫ than human Rac1 and other Rac isoforms from Zea maize when expressed in mammalian cells in vitro. Our present results showed a significant increase in ZmRacD activity in the hearts of transgenic mice. Rac1-GTPase activation may play a key role in the initiation of cardiac hypertrophy linking NADPH oxidaserelated ROS production to the hypertrophic signaling cascade (26) ; therefore, we assessed alterations in cardiac structure and function due to increased ZmRacD activity in the hearts of transgenic mice using echocardiography and MRI analyses. Both analyses were consistent and showed cardiac hypertrophy in old transgenic mice, which was further confirmed by the increased heart weight-to-body weight ratio and histopathology.
In this context, a study by Sussman et al. (36) reported a transgenic mouse model that expressed human Rac1 cDNA in the heart using the same ␣-MHC promoter. The characterization of human Rac1-expressing transgenic mice (RacET mice) revealed an unusual dichotomy: 1) rapid-onset, high-level postnatal expression that led to lethal dilated cardiomyopathy and 2) slow-onset postnatal expression leading to transient hypertrophy with survival that was evident in 3-wk-old RacET ventricles and resolved with age. However, our ZmRacD mouse model did not show any of these phenotypes, and the mice breed and develop normally until the age of 18 mo, when they start to show the above-mentioned cardiac abnormalities. Consistent with our results that showed cardiac hypertrophy with decreased systolic functions in old transgenic mice, a recent study by Adam et al. (1), who used the same RacET mice (36) , showed concentric hypertrophy with functionally depressed FS at 16 mo old. Interestingly, both Rac1 (36) or ZmRacD (present report) overexpression resulted in significantly increased expression and activation of the respective protein (Rac1 or ZmRacD) in the heart. However, it is apparent that there are differences in the intrinsic cardiac subcellular and molecular signaling pathways, which may have caused the slow onset of cardiac phenotypes in old ZmRacD mice compared with Rac1 transgenic mice. Although the mechanism of action remains to be established, the differences may be due to the incomplete homology of ZmRacD to the human counterpart (62% identity at the amino acid level) and the levels of O 2 ·Ϫ (15) . It is important to note that in hypertrophic cardiomyopathy, systolic function is typically normal or enhanced, but cardiac relaxation is impaired due to the thickened, fibrotic ventricular walls. However, dilated cardiomyopathy is characterized by ventricular chamber dilation with normal or decreased wall thickness and impaired systolic function, which often manifests as heart failure (11). Unexpectedly, old ZmRacD transgenic mice showed LV hypertrophy with relative ventricular chamber dilation, normal wall thickness, and decreased systolic function [EF: 63% vs. 77% (WT); FS: 34% vs. 45% (WT)], which is not indicative for heart failure (EF Ͻ 50% and FS Ͻ 30%). Our results are in agreement with previous reports in both animals (6) and human patients (32, 33) . Importantly, a study by Seiler et al. (32) suggested the severe LV hypertrophy is a cause for enhanced interstitial fibrosis, which results in dilated LV with systolic dysfunction.
In support of the role of NADPH oxidase in cardiac hypertrophy, it has been reported that mice with targeted disruption of gp91 phox have decreased myocardial O 2 ·Ϫ production and develop less cardiac hypertrophy in response to angiotensin II (4) . In addition, another study (31) showed that Rac1-induced NADPH oxidase activity, and not other effects of Rac1, is the main regulator of cardiac hypertrophy in response to angiotensin II. In line with the established role of the catalytic unit gp91 phox and Rac1 in the activation of NADPH oxidase activity, gp91 phox , ZmRacD expression, and GTPase activity of ZmRacD were increased in our model and associated with increased generation Fig. 7 . Activation of hypertrophic signaling. A and B: Western blot analyses of total and phosphorylated (p-)ERK1/2 (A) and total and p-JNK (B) in mouse hearts, where the value from adult WT mice was assigned as 100% (n ϭ 8 mice/group). There were no significant changes in both total ERK and total JNK among groups. *Significant change compared with adult WT mice; **significant change compared with adult and old WT mice; #significant change compared with adult transgenic mice.
of myocardial O 2 ·Ϫ in the hearts of transgenic mice. This indicates the ability of ZmRacD to function as an activator of the oxidative burst in vivo. The activation of NADPH oxidase in the hearts of ZmRacD mice may be due to the high homology in the protein domain that interacts and binds to NADPH oxidase (G2 motif, amino acids 26 -45) (15) .
Rac1 activation induces a downstream signaling cascade, such as MAPK or JNK signaling leading to hypertrophy (39) . In addition to Rac1/ROS signaling, many other signaling pathways can feed into the activation of these kinases, e.g., integrins. Integrins, collectively with a number of linked cytoskeletal proteins, join the sarcomeric contractile apparatus to the extracellular matrix across the plasma membrane and elicit intracellular signaling pathways, promoting the cardiomyocyte hypertrophy program, e.g., MAPK pathway, including ERK1/2, JNK, and p38 MAPK, which are important for mediating hypertrophic cardiac growth (25, 30) . Our present report is in agreement with these studies and showed increased expression of ␣ 1 ␤ 1 -integrins and activation of both ERK1/2 and JNK in the hearts of old transgenic mice.
ILK is a multifunctional protein kinase that physically links ␤ 1 -integrin with the actin cytoskeleton, proposing a potential mechanoreceptor role. In addition, ILK-regulated signaling has been identified as a broadly adaptive hypertrophic response mechanism related to a broad range of heart diseases (25) . Furthermore, a recent study (5) proposed that ILK is a central mediator of Rac1-induced oxidative stress and myocardial hypertrophy. Therefore, we sought to assess ILK expression in mouse hearts; however, there were no significant differences in ILK expression among the groups. This led to the assumption that increased integrin expression and the subsequent activation of hypertrophic signaling is directly dependent on Rac activity. To confirm our assumption, we treated the transgenic mice with the Rac inhibitor pravastatin. Interestingly, pravastatin significantly inhibited Rac activity without affecting total Rac expression. These results are in agreement with a previous report (1) that used another derivative of statins, rosuvastatin. In addition, ␣ 1 ␤ 1 -integrins expression in the hearts of transgenic mice was decreased to levels similar to those of control mice. In agreement with our finding, a previous report (18) showed that activation of the small GTP-binding proteins Rac and CDC42 can lead to clustering of integrins, thereby increasing integrin avidity and adhesiveness to the extracellular matrix. Furthermore, another study (19) showed the binding of Western blot analysis of Rac-GTPase activity and Rac expression in total lysates isolated from adult WT, pravastatin-treated, and untreated transgenic mouse hearts. B and C: Western blot analyses of ␣1-integrin (B) and ␤1-integrin (C) in total lysates isolated from adult WT, pravastatintreated, and untreated transgenic mouse hearts, where the value from adult WT mice was assigned as 100% (n ϭ 8 mice/group). *Significant change compared with adult WT mice; #significant change compared with adult transgenic mice. cells to the extracellular matrix is inadequate to provoke clustering of integrins, focal complex formation, and later activation of intracellular signaling pathways but requires, also, functionally active intracellular Rho-family GTPases, e.g., Rac.
Likewise, old WT mice showed significant increases in myocardial Rac1 expression and activity with subsequent increases in myocardial O 2 ·Ϫ levels, ␣ 1 ␤ 1 -integrins expression, and activation of hypertrophic signals (ERK1/2 and JNK). These cellular changes were coupled with insignificant increases in LV mass-to-body weight and heart weight-to-body weight ratios but a significant increase in the cardiomyocyte cross-sectional area, indicating a state of cellular hypertrophy. Consistence with our finding, Wang et al. (38) showed that increased endogenous myocardial Rac/NADPH oxidase activity resulted in cardiomyocyte hypertrophy in aged rats without increases in the gross heart weight. These results clearly demonstrate that both old WT and old transgenic mice share some similar pathways; however, the remodeling phenotype was accelerated in old transgenic mice due to overexpression of the ZmRacD transgene. This, in turn, indicates that the ZmRacD mouse model is a valid and valuable model that can relate changes in endogenous Rac.
Despite the significant increases in Rac-induced signaling in adult transgenic mice, only old transgenic mice showed apparent cardiac remodeling. This indicates the contribution of age and age-related increase in myocardial Rac expression in the remodeling process. In addition, the mild cardiac remodeling in old WT mice may be due to the lack of additional stress triggered by increased Rac-associated ROS production from ZmRacD. Thus, the combination of age and increased Racinduced ROS accelerated the development of cardiac hypertrophy in old transgenic mice. It is worth noting that although there was no significant difference in myocardial Rac expression levels between old WT (endogenous Rac) and adult transgenic (ZmRacD) mice, only old WT mice demonstrated cardiomyocyte hypertrophy. In addition to the age effect, this may indicate the impact of the homology differnce between mammalian Rac and ZmRacD on the induced cardiac outcome.
T 4 responsiveness of the ␣-MHC promoter has been previously reported (36, 37) . Therefore, we sought to assess the effect of T 4 supplementation on the expression of ZmRacD in the hearts of adult transgenic mice. Interestingly, our results showed increased Rac expression in the hearts of adult transgenic mice, which, in turn, evoked cardiac dilation and systolic dysfunction within the range of heart failure. Consistent with our finding, Sussman et al. (36) reported that all RacET mice that were supplemented with T 4 showed increased Rac expression and developed dilated cardiomyopathy. In contrast to our ZmRacD mice, which showed nonlethal dilated cardiomyopathy, all T 4 -treated RacET mice exhibited lethal dilated cardiomyopathy within 1.5 wk after birth. This phenotypic difference may be attributed to age differences between the mice used in the two studies or again due to the incomplete homology of ZmRacD to the human counterpart, which resulted in this milder phenotype in ZmRacD mice. Interestingly, a similar lethal phenotype was exhibited by ZmRacD mice when they were supplemented with higher doses of T 4 . Our preliminary experiments showed 70% and 33% mortality in ZmRacD mice 24 h after treatment with 1 and 0.5 mg/kg intraperitoneal T 4 , respectively (data not shown). Conversely, WT mice treated with the same high doses of T 4 did not show any of those lethal effects (data not shown).
Correspondingly, T 4 treatment resulted in increased Rac expression in adult WT mice (endogenous Rac). This might be due to the activation of phosphatidylinositol 3-kinase (PI3K), as a previous report (34) demonstrated a Rac-dependent effect of T 4 through the activation of PI3K, a well-known affecter of Rac. It is important to note that Rac expression levels in T 4 -treated adult WT (endogenous Rac) and untreated adult transgenic (ZmRacD) mice were similar. However, only T 4 -treated adult WT mice exhibited physiological cardiac hypertrophy (data not shown). This is in agreement with a previous report (10) that showed T 4 -induced cardiac hypertrophy in normal mice. Furthermore, this again confirms the effect of the homology difference between mammalian Rac and ZmRacD on the onset and type of induced cardiac effects.
On the other hand, T 4 treatment of ZmRacD mice led to a higher level of myocardial Rac expression compared with untreated adult transgenic and T 4 -treated WT mice. The high levels of Rac expression in the hearts of T 4 -treated ZmRacD mice could be due to the activation of both endogenous and transgenic Rac. Our results showed that T 4 treatment results in cardiac hypertrophy in adult WT mice and dilation in ZmRacD mice. This clearly indicates the dependence of these distinct cardiac phenotypes on the level of Rac expression. In addition, this confirms the role of elevated levels of Rac expression in the transition from cardiac hypertrophy to dilation and failure. This phenomenon is now under investigation and will be confirmed in another report.
Taken together, our results indicate the remarkable functional and structural conservation of Rho/Rac proteins between plant and animal kingdoms during evolution both in vitro (15) and in vivo (present report). In addition, the ZmRacD mouse model is a valid and valuable model that can relate changes induced by endogenous Rac. Furthermore, ZmRacD represents a unique model: the incomplete overall homology of ZmRacD to the human counterpart, but the high homology in the protein domain that interacts and binds to NADPH oxidase, enables our model to gradually develop a cardiac phenotype with aging and provide an executable window to investigate the pathological conditions involved in the progression of Rac-induced O 2 ·Ϫ in cardiovascular diseases. Finally, the shift from cardiac hypertrophy to dilated hearts via T 4 treatment provides us with an excellent system to study the temporal changes in cardiac signaling from adaptive to maladaptive hypertrophy and heart failure.
A limitation of the present study is that we did not show the effect of pravastatin treatment on the cardiac phenotype in old transgenic mice. However, we anticipate that inhibition of Rac-GTPase activity and integrins expression by pravastatin could attenuate the upregulation of hypertrophic signaling and cardiac phenotype developed in these mice. In support of this anticipation, our recent data showed that pravastatin treatment attenuated the cardiac dilation and systolic dysfunction exhibited by adult transgenic mice after ZmRacD gene expression was induced by T 4 administration (data not shown).
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